A comprehensive review of rFVIIa use in a Tertiary Care Pediatric Center

Pediatric Blood and Cancer

Volumn 50, Issue 5, 2008, Pages 1013-1017

  Heller, Mariel ^a   Lau, Wendy ^b   Pazmino Canizares, Janneth ^a,c   Brandão, Leonardo R ^a   Carcao, Manuel ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Off label usage; Pediatrics; rFVIIa

Indexed keywords

HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BERNARD SOULIER DISEASE; BLEEDING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CONTROLLED STUDY; DRUG INDICATION; GLANZMANN DISEASE; HEMOPHILIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TERTIARY HEALTH CARE; THROMBOCYTE FUNCTION;

ADOLESCENT; BLOOD PLATELET DISORDERS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FACTOR VII DEFICIENCY; FACTOR VIIA; FEMALE; HEMOPHILIA A; HEMORRHAGE; HOSPITALS, PEDIATRIC; HUMANS; INFANT; INFANT, NEWBORN; MALE; RECOMBINANT PROTEINS; REGISTRIES;

EID: 41849083832     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21375     Document Type: Article

References (22)

1. Mathew P, Young G. Recombinant factor VIIa in paediatric bleeding disorders - A 2006 review. Haemophilia 2006;12:457-472.
2. Association of Hemophiliac Clinic Directors of Canada. Available at: www.ahcdc.ca. (accessed 2006 Nov 14).
3. Blatt J, Gold SH, Wiley JM, et al. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001;28:405-407.
4. MacLaren R, Weber LA, Brake H, et al. A multicenter assessment of recombinant factor VIIa off-label use: Clinical experiences and associated outcomes. Transfusion 2005;45:1434-1442.
5. Ghorashian S, Hunt BJ. "Off-license" use of recombinant activated factor VII. Blood Reviews 2004;18:245-259.
6. Mathew P. The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. Thromb Haemost 2004;92:738-746.
7. Chuansumrit A, Suwannuraks M, Sri-Udomporn N, et al. Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis 2003;14:183-190.
8. Berettini M, Mariano G, Schiavoni M, et al. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. Haematologica 2001;86:640-645.
9. Mariani G, Testa MG, Di Paolantonio T, et al. Use of recombinant activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang 1999;77:131-136.
10. Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: A report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005;3:640-648.
11. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005;59:8-15.
12. Chuansumrit A, Visanuyothin N, Puapunwattana S, et al. Outcome of intracranial hemorrhage in infants with congenital factor VII deficiency. J Med Assoc Thai 2002;85:S1059-S1064.
13. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII intracerebral hemorrhage trial investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-785.
14. Mayo A, Misgav M, Kluger Y, et al. Recombinant activated factor VII (NovoSeven™): Addition to replacement therapy in acute, uncontrolled and life-threatening bleeding. Vox Sang 2004;87:34-40.
15. Barnes C, Blanchette V, Canning P, et al. Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med 2005;15:145-150.
16. Veldman A, Fischer D, Voigt B, et al. Life-threatening hemorrhage in neonates: Management with recombinant activated factor VII. Intensive Care Med 2002;28:1635-1637.
17. Macdonald JA, Fraser JF, Foot CL, et al. Successful use of recombinant factor VII in massive hemoptysis due to community-acquired pneumonia. Chest 2006;130:577-579.
18. International Factor VII Study Group. Seven Treatment Evaluation Registry. Available at http://www.targetseven.org. accessed 2006 11, 01
19. International Society on Thrombosis and Haemostasis Seven A in Non-Hemophilia Bleeding in Pediatrics Registry. Available at http://www.isth.org accessed 2006 11, 01.
20. Abshire T, Kenet G. Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004;2:899-909.
21. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004;104:3858-3864.
22. O'Connel KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VII. JAMA 2006;295:293-298.